Protocol Number; CINC280AJP01
Not Applicable
Recruiting
- Conditions
- MET exon 14 skipping mutation-positive unresectable advanced/recurrent non-small cell lung cancer
- Registration Number
- JPRN-jRCT2031200409
- Lead Sponsor
- Sugimoto Toshiya
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
All patients receiving Tabrecta for MET exon 14 skipping mutation-positive unresectable advanced/recurrent NSCLC during a specified post-marketing period
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.Number of patients with adverse reactions [ Time Frame: 1 year ]<br>2.Response rate [ Time Frame: 1 year ]<br>3.Overall survival rate [ Time Frame: 1 year ]<br>4.Progression-free survival (PFS) [ Time Frame: 1 year ]
- Secondary Outcome Measures
Name Time Method